Genzyme invests further in Fabrazyme as Shire fights to keep market share
This article was originally published in Scrip
Executive Summary
Genzyme (Sanofi) is planning to invest $80m for the construction of a new manufacturing facility in Framingham, Massachusetts for its Fabry drug Fabrazyme (agalsidase beta), which it believes is back on track following manufacturing setbacks.